Entrada Therapeutics Inc (TRDA)
17.76
+0.16
(+0.88%)
USD |
NASDAQ |
Nov 04, 16:00
17.76
0.00 (0.00%)
Pre-Market: 20:00
Entrada Therapeutics Cash from Investing (Quarterly): -24.38M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -24.38M |
| March 31, 2024 | 26.15M |
| December 31, 2023 | 19.04M |
| September 30, 2023 | -3.737M |
| June 30, 2023 | -113.26M |
| March 31, 2023 | -40.44M |
| December 31, 2022 | 18.79M |
| Date | Value |
|---|---|
| September 30, 2022 | -10.13M |
| June 30, 2022 | 24.22M |
| March 31, 2022 | -181.53M |
| December 31, 2021 | -1.322M |
| September 30, 2021 | -0.806M |
| June 30, 2021 | -1.544M |
| March 31, 2021 | -0.908M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-181.53M
Minimum
Mar 2022
26.15M
Maximum
Mar 2024
-20.70M
Average
-1.433M
Median
Cash from Investing (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | -12.51M |
| Sarepta Therapeutics Inc | -98.53M |
| Catalyst Pharmaceuticals Inc | -0.01M |
| Vertex Pharmaceuticals Inc | -463.70M |
| Regenxbio Inc | -0.268M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 39.83M |
| Cash from Financing (Quarterly) | 101.37M |
| Free Cash Flow | -18.50M |
| Free Cash Flow Per Share (Quarterly) | 1.092 |
| Free Cash Flow to Equity (Quarterly) | 38.79M |
| Free Cash Flow to Firm (Quarterly) | 38.79M |
| Free Cash Flow Yield | -3.01% |